Patients over 60 years old have less ability to compensate for changes in blood flow or energy needs of the optic nerve

Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.[1][2] It has a molecular weight of approximately 4,800 Da and is administered subcutaneously, with a half-life supporting once-weekly dosing.[3][4] Developed by Eli Lilly, it is currently in Phase 3 clinical trials for obesity and type 2 diabetes (T2D), showing potential for superior weight loss compared to existing therapies.[1][5] Key characteristics for compounding pharmacies include: Multi-Receptor Agonist : Combines actions of GIP, GLP-1, and glucagon for enhanced metabolic effects.[1][6] Lyophilized Form : Supplied as a stable powder for reconstitution, similar to other peptides.[7][8] Versatile Delivery : Primarily subcutaneous, but potential for customized formulations in research contexts.[7][9] This makes Retatrutide a candidate for specialized preparations in compounding settings, though regulatory restrictions apply

However, the effectiveness of natural products has not been definitively established as chemopreventive agents for primary and secondary cancer prevention
The Benefits of L-Carnitine L-carnitine supplementation has proven effective in: Reducing fatigue and preserving cell energy levels Enhancing cardiovascular function and heart muscle strength Promoting weight loss , impacting of obesity and diabetes Improving body composition Lowering blood sugar levels Delaying or reversing brain degeneration, slowing signs of brain aging
Subjects then engaged in a moderate 5-week exercise training program twice per week with the final training session on the fifth week of supplementation consisting of a supervised lower-body exercise challenge specifically constructed to induce muscle damage